Clinical Trial Update: Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the combination of CPX-351 (liposomal cytarabine and daunorubicin) with Quizartinib for acute myeloid leukemia and high…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome
• Myelodysplastic Syndrome

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)
• Quizartinib (Quizartinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells | Phase 1, Phase 2 | Status: RECRUITING